Institutional members access full text with Ovid®

Share this article on:

Cryptogenic Stroke and Patent Foramen Ovale

Jaigobin, Cheryl MD

doi: 10.1212/01.CON.0000410039.72594.03
Practice Issues

ABSTRACT In patients with cryptogenic stroke and patent foramen ovale, options for stroke prevention include medical therapy (antiplatelet therapy or anticoagulation) and percutaneous device closure. In the only completed randomized controlled trial comparing medical therapy and percutaneous device closure, there was no difference in outcome between the two forms of treatment, and both are viable options for stroke prevention. The choice of therapy is made after careful weighing of potential risks and benefits associated with each form of therapy based on the limited evidence to date and the anticipated patient adherence with the planned treatment. Participation in a clinical trial is a third option for these patients.

Address correspondence to Dr Cheryl Jaigobin, Toronto General Hospital, 5 Eaton Centre-Room 306, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada, cheryl.jaigobin@uhn.on.ca.

Relationship Disclosure: Dr Jaigobin reports no disclosure.

Unlabeled Use of Products/Investigational Use Disclosure: Dr Jaigobin reports no disclosure.

© 2011 American Academy of Neurology
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website